Monitoring the Efficacy of Anthelmintics for the Treatment of Soil Transmitted Helminths P2

NCT ID: NCT01379326

Last Updated: 2014-12-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

250 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-12-31

Study Completion Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Objectives:

The overall objective is to monitor efficacy of mebendazole (MBZ) against Soil-Transmitted Helminths (STH).

The primary objective is:

(1) to monitor the efficacy a single dose 500 mg of mebendazole (MBZ) against Soil-Transmitted Helminths (STH) infections by means of Faecal Egg Count Reduction (FECR) and Cure Rate (CR).

The secondary objectives are:

1. to assess the occurrence of Necator americanus and Ancylostoma duodenal.
2. to assess the occurrence of β-tubulin mutations related to resistance before and after drug administration.
3. to evaluate the role of dogs and pigs as reservoir for zoonotic transmission.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary objective:

Following obtaining informed consent, schoolchildren in the target age range group will be recruited and asked to provide a recent stool sample (an interval of less than 4 hours) that will be processed to determine the Faecal Egg Count (FEC) for each Soil-Transmitted Helminths (STH) present. For the initial sampling the aim is to enroll at least 250 infected children for at least one of the Soil-Transmitted Helminths (STH). This sample size was selected based on statistical analysis of study power, using random simulations of correlated over-dispersed Faecal Egg Count data reflecting the variance-covariance structure in a selection of real Faecal Egg Count (FEC) data sets. This analysis suggested that a sample size of up to 200 individuals (α = 0.05, power = 80%) was required to detect a 10 percentage point drop from a null efficacy of \~ 80% (mean percentage FEC ∆ per individual) over a wide range of infection scenarios. Standard power analyses for proportions also indicated that the detection of a \~10 percentage point drop from a null cure rate required sample sizes up to 200 (the largest samples being required to detect departures from null efficacies of around 50%). Given an anticipated non-compliance rate of 25%, a sample of 250 infected subjects was therefore considered necessary at each study site.

All children providing stool samples will be treated with mebendazole (MBZ) single table of 500mg under supervision (chewing + water). The mebendazole (MBZ) will be provided (free) by the coordinating group. Seven up to fourteen days (maximum interval) after treatment a second faecal sample will be collected from the children to determine again FEC. Subjects who are unable to provide a stool sample at follow-up, or who are experiencing a severe concurrent medical condition or have diarrhea at time of the first sampling, will be excluded from the study.

Secondary objectives:

In 5 study sites, faecal samples of 100 infected subjects should be preserved before treatment with mebendazole (MBZ) in one tube (1 gram in 10 ml 70% ethanol). Samples of the same children should be also preserved again in one tube (1 gram in 10 ml 70% ethanol) after treatment. Samples have be send to the Laboratory of Parasitology, Ghent University.

The samples, collected before and after treatment will be subsequently examined by molecular assays the occurrence Necator americanus/Ancylostoma duodenal and the occurrence of β-tubulin mutations related to resistance.

The samples collected before treatment will be subsequently examined by molecular assays to assess the role of animals as a reservoir for human Soil-Transmitted Helminths (STH).

Parasitological techniques, determination of Faecal Egg Count of Soil-Transmitted Helminths (STH). All fecal samples were processed using the McMaster egg counting technique for the detection and the enumeration of infections with A. lumbricoides, T. trichiura and hookworms. All study sites are familiar with the technique and McMaster slides were provided previously.

Molecular assays (Laboratory of Parasitology, Ghent University)and Deoxyribonucleic acid (DNA) extraction.

DNA of Soil-Transmitted Helminths (STH) will be extracted from the samples preserved in ethanol 70% using the Qiagen mini stool kit.

Molecular identification of Soil-Transmitted Helminths (STH). The presence of the Soil-Transmitted Helminths species: Ascaris (n= 2), Trichuris (n = 2) and hookworms (n = 4) will be assessed using different molecular assays. For the differentiation of Trichuris species, species-specific polymerase chain reaction (PCR) will be applied. For the differentiation of Ascaris and the canine hookworms a PCR-Restriction Fragment Length Polymorphism (PCR-RFLP) will be used. For the human hookworms, a quantitative PCR will be applied.

Presence of mutations in β-tubulin related to mebendazole (MBZ) resistance This specific objective will be performed in collaboration with McGill University (Canada).

Statistical analysis. Both Cure Rate (CR) and Faecal Egg Count Reduction (FECR) will be considered to monitor to efficacy of mebendazole (MBZ) against Soil-Transmitted Helminths. The statistical analysis will be assessed as described by Vercruysse et al., 2011.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ascaris Lumbricoides Ascaris Suum Trichuris Trichiura Trichuris Vulpis Ancylostoma Duodenal Ancylostoma Caninum Ancylostoma Ceylanicum Necator Americanus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Mebendazole

Group Type EXPERIMENTAL

Mebendazole

Intervention Type DRUG

All children providing stool samples will be treated with mebendazole single table of 500mg under supervision (chewing + water).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Mebendazole

All children providing stool samples will be treated with mebendazole single table of 500mg under supervision (chewing + water).

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Exclusion Criteria

* Subjects who are unable to provide a stool sample at follow-up
* Subjects who are experiencing a severe concurrent medical condition
* Subjects with diarrhea at first sampling
Minimum Eligible Age

4 Years

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Commonwealth Scientific and Industrial Research Organisation, Australia

OTHER_GOV

Sponsor Role collaborator

World Health Organization

OTHER

Sponsor Role collaborator

Institut Pasteur, Cambodia

OTHER

Sponsor Role collaborator

The University of Queensland

OTHER

Sponsor Role collaborator

Oswaldo Cruz Foundation

OTHER

Sponsor Role collaborator

University of Nottingham

OTHER

Sponsor Role collaborator

University of Yaounde 1

OTHER

Sponsor Role collaborator

Ivo de Carneri, Pemba Island, Tanzania

UNKNOWN

Sponsor Role collaborator

National Institute of Malariology, Parasitology and Entomology, Vietnam

OTHER_GOV

Sponsor Role collaborator

Jimma University

OTHER

Sponsor Role collaborator

Fundación Huésped

OTHER

Sponsor Role collaborator

Queensland Institute of Medical Research

OTHER

Sponsor Role collaborator

Institut Pasteur

INDUSTRY

Sponsor Role collaborator

University Ghent

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Fundacion Huesped

Buenos Aires, , Argentina

Site Status

Commonwealth Scientific and Industrial Research Organisation

Brisbane, , Australia

Site Status

Queensland Institute for Medical Research, University of Queensland

Herston QLD, , Australia

Site Status

Fundação Oswaldo Cruz

Belo Horizonte, , Brazil

Site Status

Institut Pasteur in Cambodia, Clinical Pathology Unit

Phnom Penh, , Cambodia

Site Status

University of Yaoundé I

Yaoundé I, , Cameroon

Site Status

College of Public Health and Medical Sciences, Jimma University

Jimma, , Ethiopia

Site Status

Ivo de Carneri, Pemba Island

Zanzibar, , Tanzania

Site Status

National Institute for Malariology, Parasitology and Entomology

Hanoi, , Vietnam

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Switzerland United Kingdom Argentina Australia Brazil Cambodia Cameroon Ethiopia Tanzania Vietnam

References

Explore related publications, articles, or registry entries linked to this study.

Levecke B, Montresor A, Albonico M, Ame SM, Behnke JM, Bethony JM, Noumedem CD, Engels D, Guillard B, Kotze AC, Krolewiecki AJ, McCarthy JS, Mekonnen Z, Periago MV, Sopheak H, Tchuem-Tchuente LA, Duong TT, Huong NT, Zeynudin A, Vercruysse J. Assessment of anthelmintic efficacy of mebendazole in school children in six countries where soil-transmitted helminths are endemic. PLoS Negl Trop Dis. 2014 Oct 9;8(10):e3204. doi: 10.1371/journal.pntd.0003204. eCollection 2014 Oct.

Reference Type DERIVED
PMID: 25299391 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2011/374

Identifier Type: -

Identifier Source: org_study_id